A Phase II Trial For Neutron Capture Therapy In Melanoma
- Determine the clinical response, by serial objective measurements, in patients with
melanoma treated with boron neutron capture therapy.
- Determine the time course, uniformity, and severity of acute dermal reactions in
patients treated with this regimen.
- Determine the late dermal reactions in patients who are followed for at least 6 months
after treatment with this regimen.
- Determine the pharmacokinetics of this regimen in these patients.
OUTLINE: Patients are stratified according to tumor size (no greater than 15 cc vs greater
than 15 cc).
Patients undergo boron neutron capture therapy.
Patients are followed for 3 years.
PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.
Allocation: Non-Randomized, Primary Purpose: Treatment
Paul M. Busse, MD, PhD
Beth Israel Deaconess Medical Center
United States: Federal Government
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Massachusetts Institute of Technology||Cambridge, Massachusetts 02139|